Using AI to screen for diabetic retinopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the effectiveness of an artificial intelligence-based software platform, Retina-AI, in detecting diabetic retinopathy (DR). Participants will have fundus images taken with a non-mydriatic camera, following a specific imaging protocol. These images will then be uploaded to the AI system for analysis by a neural network to assess the presence of DR. The goal is to evaluate the accuracy and reliability of this AI tool in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Documented diagnosis of diabetes mellitus by definition.
2. Understanding of the Study and willingness and ability to sign informed consent
3. Patient age 18 or above
4. Diagnostic for diabetes: 4a) Type 1 diabetes of a lest 5 years of evolution; or 4b) Type 2 diabetes

Exclusion Criteria:

-1. Patients under 18 years of age; 2. Failure to give informed consent; 3. Presence of retinal diseases - acquired disease: age-related macular degeneration (AMD), occlusion of retinal vessels (ORV), etc.; birth defects: coloboma of choroid or optic nerve disc, etc.; hereditary diseases: retinitis pigmentosa, angioid streaks of the retina, etc.

4\. A patient who has already undergone treatment (surgery, laser, etc.) for any disease of the retina: age-related macular degeneration (AMD), retinal vascular occlusion (ARV), etc. These patients should be excluded or allocated to a separate group.

Where it's running

• The Filatov Institute of Eye Diseases and Tissue Therapy
  Odesa, Ukraine Recruiting

Study contacts

• Principal investigator: Andrii MD Korol, PhD — The Filatov Institute of Eye Diseases and Tissue Therapy
• Study coordinator: Andrii MD Korol, PhD
• Email: andrii.r.korol@gmail.com
• Phone: 380936327266

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Corticosteroid for Diabetic Macular Edema (DME) in Adults with Diabetic Retinopathy

  This trial tests whether intravitreal corticosteroid injections can influence inflammatory biomarkers and improve DME in adults with type 2 diabetes.

  Recruiting Phase 4 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07843849

• Automated detection of diabetic retinopathy lesions in fundus photos

  This study tests a smart imaging system within the DDART device to see if it can reliably spot diabetic retinopathy lesions in color fundus photographs.

  Recruiting Democritus University of Thrace · Alexandroupoli · NCT07758582

• Retinal microvascular changes in diabetic retinopathy measured with OCTA

  This observational study tests how retinal blood vessel patterns seen on OCTA relate to vision and blood sugar control in adults with diabetic retinopathy.

  Recruiting Sohag University · Sohag · NCT07747428

• MK-8748 vs. aflibercept for diabetic macular edema

  This trial tests whether the investigational medicine MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in adults with diabetes.

  Recruiting at 20 sites Phase 3 Merck Sharp & Dohme LLC · Long Beach, California and 19 other locations · NCT07705607

• MK-8748 vs aflibercept for diabetic macular edema

  This trial tests whether MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in people with diabetes.

  Recruiting at 35 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 34 other locations · NCT07705555

• Surabgene Lomparvovec in the Suprachoroidal Space for Diabetic Retinopathy

  This study tests a one-time gene therapy called surabgene lomparvovec to see if it can help adults with non-proliferative diabetic retinopathy avoid vision-threatening events.

  Recruiting at 40 sites Phase 2/3 AbbVie · Mesa, Arizona and 39 other locations · NCT07592273

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.